Current Scheduling Status
None
Year(s) and type of review / ECDD meetings
Drug Class
Recommendation (from TRS)
Substance identification
Prazitone (INN,. CAS-2409-26-9), chemically 5-phenyl-5-(2-piperidylmethyl)-barbituric acid, has no common names. It is a racemic mixture.
Similarity to known substances and effects on the CNS
No data are available.
Dependence potential
No data are available.
Actual abuse and or/evidence of likelihood of abuse
There have been no reports of abuse, trafficking, or clandestine manufacture. The drug is under national control in five countries.
Therapeutic usefulness
No data are available concerning the therapeutic use of prazitone. There is no evidence that the drug is available for medical use.
Recommendation
The Committee found that there was insufficient evidence that prazitone is being, or is likely to be, abused so as to constitute a public health and social problem warranting the placing of the substance under international control. The Committee rated the likelihood of abuse of prazitone as indeterminate. The degree of the public health and social problems
associated with the drug was found to be low as was its therapeutic usefulness. In the light of this assessment, the Committee recommended against scheduling of the drug.
Prazitone (INN,. CAS-2409-26-9), chemically 5-phenyl-5-(2-piperidylmethyl)-barbituric acid, has no common names. It is a racemic mixture.
Similarity to known substances and effects on the CNS
No data are available.
Dependence potential
No data are available.
Actual abuse and or/evidence of likelihood of abuse
There have been no reports of abuse, trafficking, or clandestine manufacture. The drug is under national control in five countries.
Therapeutic usefulness
No data are available concerning the therapeutic use of prazitone. There is no evidence that the drug is available for medical use.
Recommendation
The Committee found that there was insufficient evidence that prazitone is being, or is likely to be, abused so as to constitute a public health and social problem warranting the placing of the substance under international control. The Committee rated the likelihood of abuse of prazitone as indeterminate. The degree of the public health and social problems
associated with the drug was found to be low as was its therapeutic usefulness. In the light of this assessment, the Committee recommended against scheduling of the drug.
ECDD Recommendation
Scheduling/control not currently recommended
Link to full TRS
who_trs_741.pdf2.21 MB